According to the new study of the researchers, there is a drug that can help produce new brain cells. In addition to this, this can also lead them to expand the experimental study about the drug that can be used in Alzheimer’s disease.

Moreover, according to this study, they also find that all mammals including humans can construct new cells in the brain as long as they live. However, many of the new brain cells die yet it can last through taking the rodents that can help the new cells to keep them alive.

As Andrew Peiper, one of the researchers that work on the study said that humans can create new neurons everyday and the problem with this situation is how they can stay alive to grow. In addition to this, they can up a compound that can help brain cells to continue their growth.

This compound is also known as P7C3, and Pieper’s team are still working on it to make it more useful with the brain cells. They also said that there is nothing to worry about taking this as a pill because it is safe.
The effect of the compound is almost the same as the experimental drug for Alzheimer’s disease, Dimebon. Moreover, it is also like to other compounds that are created by Serono.

The product of Pfizer Inc. and Medivation Inc., Dimebon actually originated in Russia for antihistamine failed in clinical trial for curing Alzheimer’s disease last March.

The researchers also added that if the two pharmaceutical companies created the Dimebon to help cure the Alzheimer’s disease but did not pass the clinical trial test, they are hoping that with the developing and improving of the compound they can help those who have brain diseases like Alzheimer’s disease.

According to the new study, people with multiple sclerosis feel almost 50 percent possibility of having depression because of brain atrophy or the shrinking of the brain. It takes place in hippocampus, a part where the memory and mood is functioning.

The researchers from California University in Los Angeles said that they make use of MRI scan to evaluate healthy people with those who have multiple sclerosis (MS). The result of the scan shows that people who have MS have smaller three sub-parts of the hippocampus rather than those who do not multiple sclerosis.

Researchers also found a link between the hyperactivity of the hypothalamic pituitary ardenal (HPA) axis and brain atrophy. The hypoythalamic pituitary adrenal manipulates reactions to control most of the function of physiological and stress. The researchers also added that too much activity of the hypothalamic pituitary adrenal axis can be connected with the atrophy of hippocampus and the depression’s growth.

However, the connection of brain atrophy and HPA too much activity has not yet obtain much attention. Dr. Nancy Sicotte, an instructor in neurology, said that the majority reliability findings about having depression without MS and psychiatric patients involve much activity of hypothalamic pituitary adrenal axis and the shrinking of hippocampus.

Sicotte also added that in order to see the development of psychiatric patients that have depression with MS patients that have also depression is to compare them both.

According to Stefan Gold, author of UCLA Multiple Sclerosis Program, patients who have multiple sclerosis and psychiatric patients also share most of the usual signs of impacts cognitive purpose, depression, value of life, good performance in work and medicate observance. In addition to this, the worst scenario of patients who have multiple sclerosis is attempting suicide.